Carnegie Investment Counsel Purchases New Shares in CVS Health Corporation $CVS

Key Points

• Carnegie Investment Counsel purchased a new stake of 48,695 shares of CVS Health in Q4, valued at about $3.86 million according to its latest Form 13F filing.
• Institutional investors now own about 80.66% of CVS, with several other funds making modest buys and sells recently, indicating continued institutional interest in the stock.
• Analysts maintain a consensus of "Moderate Buy" (20 Buys, 3 Holds) with an average price target of $94.95; CVS also announced a quarterly dividend of $0.665 (annualized $2.66) yielding ~3.4% (ex-dividend Apr 23, payable May 4).

Carnegie Investment Counsel purchased a new stake in CVS Health Corporation (NYSE:CVS - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 48,695 shares of the pharmacy operator's stock, valued at approximately $3,864,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Harbor Capital Advisors Inc. raised its position in CVS Health by 72.1% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator's stock valued at $26,000 after buying an additional 142 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its position in CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator's stock valued at $26,000 after buying an additional 281 shares during the last quarter. Corundum Trust Company INC purchased a new stake in CVS Health in the 3rd quarter valued at $29,000. Front Row Advisors LLC raised its position in CVS Health by 436.5% in the 2nd quarter. Front Row Advisors LLC now owns 456 shares of the pharmacy operator's stock valued at $31,000 after buying an additional 371 shares during the last quarter. Finally, GoalVest Advisory LLC purchased a new stake in CVS Health in the 4th quarter valued at $32,000. 80.66% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

CVS has been the subject of a number of analyst reports. Leerink Partners reissued an "outperform" rating and issued a $98.00 price target on shares of CVS Health in a research report on Thursday, March 5th. Piper Sandler lowered their price target on CVS Health from $101.00 to $99.00 and set an "overweight" rating for the company in a research report on Tuesday, March 31st. Wolfe Research decreased their target price on CVS Health from $100.00 to $97.00 and set an "outperform" rating for the company in a research report on Monday, March 2nd. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of CVS Health in a research report on Monday, December 29th. Finally, Bank of America decreased their target price on CVS Health from $100.00 to $95.00 and set a "buy" rating for the company in a research report on Tuesday, January 27th. Twenty analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $94.95.

CVS Health Trading Up 0.6%

Shares of CVS Health stock opened at $79.29 on Friday. CVS Health Corporation has a 1 year low of $58.35 and a 1 year high of $85.15. The firm has a market cap of $101.61 billion, a PE ratio of 57.45, a P/E/G ratio of 0.83 and a beta of 0.51. The stock has a fifty day moving average price of $75.92 and a 200-day moving average price of $77.80. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.84 and a quick ratio of 0.63.

CVS Health (NYSE:CVS - Get Free Report) last announced its earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.09. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The firm had revenue of $105.69 billion during the quarter, compared to analyst estimates of $103.67 billion. During the same period last year, the firm posted $1.19 EPS. The business's revenue was up 8.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Equities research analysts anticipate that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, May 4th. Investors of record on Thursday, April 23rd will be issued a $0.665 dividend. The ex-dividend date of this dividend is Thursday, April 23rd. This represents a $2.66 annualized dividend and a yield of 3.4%. CVS Health's dividend payout ratio (DPR) is 192.75%.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.